Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Recruiting now

Conditions studied: Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation

In brief

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Key facts

Study ID

NCT06783127

Run by

Santa Chiara Hospital

People needed

3000

Starts

2023-01-01

Expected to finish

2026-12-31

Last updated by the study team

2025-02-11

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice

You may not qualify if…

• Olaparib treatment in a clinical trial

Where it is running

• Sabrina Rossetti — Naples, Italy (enrolling)
• Orazio Caffo — Trento, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.